ACC 2019 | TAVR in Low-Risk Patients Is Noninferior

Courtesy of Dr. Carlos Fava.

Self-expanding supraannular aortic valves have proved to be superior to surgery in high-risk patients and noninferior in intermediate-risk patients. However, the current challenge is posed by low-risk, generally younger, patients. In that sense, our purpose is to determine device effectiveness and safety in terms of mortality and stroke rates (which are low with surgery), their risk for complications, and—particularly—their durability.

ACC 2019 | Prometedores resultados para el TAVI en bajo riesgoThis was a multicenter study that enrolled patients with severe aortic stenosis who were randomized 1:1 to transcatheter aortic valve replacement (TAVR) with CoreValve, Evolut R, or Evolut PRO (Medtronic) vs. aortic valve surgery.

 

The primary endpoint was a composite of death or disabling stroke at 24 months, and the secondary safety endpoint at 30 days was a composite of death, disabling stroke, major cardiovascular complications, life-threatening bleeding, and stage 2 or 3 acute renal failure.


Read also: TAVR in Low-Risk Patients with “Zero” Mortality and “Zero” Stroke.


Originally, each group had been assigned 734 randomized patients, but 12 subjects were excluded from the TAVR group and 53 from the surgery group. Ultimately, there were 725 patients in the TAVR group and 678 in the surgery group.

 

Patient characteristics were similar and the mean age was 74 years. Only 39% of patients were female; 30% had diabetes; 5% had a prior infarction; 2.2% had undergone prior myocardial revascularization surgery (MRS), and the Society of Thoracic Surgery predicted risk of mortality was 1.9%.

 

At 30 days, patients who underwent TAVR had a lower incidence of stroke (0.5% vs.1.7%), bleeding (2.4% vs. 7.5%), acute kidney injury (0.9% vs. 2.8%), and atrial fibrillation (7.7% vs. 35.4%), but a higher incidence of severe or moderate aortic regurgitation (3.5% vs. 0.5%), and new pacemaker implantation (17.4% vs. 6.1%).


Read also: EuroPCR 2018 | NOTION: Good TAVR Durability Compared with Surgically-Implanted Valve in Low-Risk Patients.


At one year, there were no differences in the rates of stroke, endocarditis, bioprosthetic-valve thrombosis, or reintervention. The Doppler echocardiography showed lower aortic-valve gradients and larger effective orifice areas (8.6 mmHg vs.11.2 mmHg and 2.3 cm2 vs. 2.0 cm2).

 

After a 24-month follow-up, there were no differences in the primary endpoint: 5.3% for the TAVR group and 6.7% for the surgery group, thus meeting noninferiority criteria (difference, −1.4 percentage points; 95% Bayesian credible interval for the difference, −4.9 to 2.1; posterior probability of noninferiority, >0.999). The mortality rate was 4.5% for both groups and the disabling stroke rates were 1.1% vs. 3.5%.

 

Conclusion

In patients with severe aortic stenosis who are at low surgical risk, TAVR with a self-expanding supraannular bioprosthesis was noninferior to surgery regarding the composite endpoint of death or disabling stroke at 24 months.  

 

Courtesy of Dr. Carlos Fava.

 

Original title: Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients.

Reference: Jeffrey J. Popma et al. N Eng J Med DOI: 10.1056/NEJMoa1816885.

 

Evolut-Low-Risk

Evolut-Low-Risk-presentacion


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...